undamentalytics Newsletter
Sign in

Alnylam Pharmaceuticals, Inc. revenue

Alnylam Pharmaceuticals, Inc.'s revenue was $3.71bn in fiscal 2025, up 65.2% on the year before. Since fiscal 2008 ($96.2m) it has grown at a compound 35.6% a year.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2008Dec 20082009Dec 20092010Dec 20102016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Revenue961011004790752204938441,0371,8282,2483,714
Growth on the year before—+4.5%−0.5%−52.9%+90.7%−16.7%+193.4%+124.3%+71.3%+22.9%+76.2%+23.0%+65.2%
Gross profit————90731954197298971,5601,9423,037
Gross margin————100.0%97.6%88.6%84.9%86.4%86.5%85.3%86.4%81.8%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Products $3B 80.4% ▲ 81.4%
TTR $2.5B 83.3% ▲ 103.3%
Rare $500M 16.7% ▲ 18.2%
Collaborations $553M 14.9% ▲ 8.5%
ONPATTRO $173M 4.7% ▼ 31.7%

From Alnylam Pharmaceuticals, Inc.'s 10-K filed February 12, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Alnylam Pharmaceuticals, Inc. $3.71bn 65.2% 53.0%
Neurocrine Biosciences Inc $3.70bn 38.0% 27.5%
Biomarin Pharmaceutical Inc $3.41bn 11.2% 15.1%
Argenx SE $4.15bn 89.9% —
Biontech SE $3.24bn 9.0% —
United Therapeutics Corp $3.15bn 2.5% 14.3%

Compare with peers

Head to head: ALNY vs NBIXALNY vs BMRNALNY vs ARGX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Alnylam Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Alnylam Pharmaceuticals, Inc.